Adjuvant Pembrolizumab for Intermediate- and High-Risk Renal Cell Carcinoma
Sumanta “Monty” K. Pal, MD, FASCO, discuss exciting data in the renal cell carcinoma space.
First-Line Treatment for Advanced Clear Cell RCC: Key Takeaways
Closing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.
Triplet Regimens in Advanced RCC in the Frontline Setting
Shared insight on the data from the COSMIC-313 trial and the potential for first-line triplet regimens in patients with advanced clear cell renal cell carcinoma.
Selecting Treatment for Advanced RCC in Second Line and Beyond
Panelists identify second-line treatment options they would consider in advanced clear cell RCC if a patient progresses following first-line therapy.
Adjuvant Immunotherapy in Advanced Renal Cell Carcinoma
Expert hematologist/oncologists consider the potential role for adjuvant immunotherapy in patients with advanced clear cell renal cell carcinoma.
First-Line Treatment in Advanced RCC: Sequencing Therapy
Focused discussion on the selection of first-line therapy for advanced clear cell renal cell carcinoma based on sites of metastasis.
First-Line Treatment in Advanced RCC: Quality of Life Considerations
Expert panelists consider the importance of quality of life when selecting first-line treatment regimens for patients with advanced clear cell renal cell carcinoma.
Optimizing Dosing of First-Line IO-TKI Therapy in Advanced RCC
Shared insight on optimal dosing strategies with first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced clear cell renal cell carcinoma.
First-Line Treatment for Advanced RCC: Cabozantinib + Nivolumab
Sumanta Pal, MD, an expert hematologist/oncologist, evaluates the combination of cabozantinib + nivolumab as first-line therapy for advanced clear cell renal cell carcinoma.
First-Line Treatment for Advanced RCC: Lenvatinib + Pembrolizumab
Centering discussion around the combination of lenvatinib + pembrolizumab in advanced clear cell RCC, Hans Hammers, MD, considers the role of this combination regimen in the first-line treatment setting.
Overview of the Treatment Landscape in Advanced Clear Cell RCC
Expert hematologist/oncologist Brian Rini, MD, spearheads a comprehensive discussion on the broad treatment landscape for advanced clear cell renal cell carcinoma.
COSMIC-021 Trial Reveals Encouraging Safety and Efficacy in Urothelial Carcinoma
Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.
Study Design of COSMIC-021 in Advanced Urothelial Carcinoma
Sumanta K. Pal, MD, discusses the methods and design of the COSMIC-021 study.
Treatment Considerations for Patients With Metastatic Urothelial Carcinoma
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
Choosing Second-Line Therapy for Patients With Urothelial Carcinoma
Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses choosing second-line therapy for patients with urothelial carcinoma.
2 Clarke Drive Cranbury, NJ 08512